IP Library Granted Patent US 8,476,316
Granted Patent B2
US 8,476,316 · App. 13/324,777 · Granted Jul 2, 2013

3-methanesulfonylpropionitrile for treating inflammation and pain

Inventor: Joseph St. Laurent (Lakeville, MA)
Assignee: Olatec Industries LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,476,316
App. No.
13/324,777
Granted
Jul 2, 2013
Kind
B2
Abstract

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Claims (9)

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a purified compound of 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof:

wherein the compound has at least 90% (w/w) purity, and the composition is in a topical form of gels, creams, lotions, or patches.

2. The pharmaceutical composition of claim 1 , wherein the compound is at least 95% (w/w) pure.

3. The pharmaceutical composition according to claim 1 , the compound is in an amount of about 0.5-10% (w/w).

4. The pharmaceutical composition of claim 1 , wherein the compound is at least 98% (w/w) pure.

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethylether, caprylic/capric triglyceride, octisalate, silicone fluid, Squalene, and sunflower oil.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethylether.

7. The pharmaceutical composition according to claim 6 , wherein the permeation enhancer is diethylene glycol monoethylether.

8. The pharmaceutical composition according to claim 6 , further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.

Assignments (3)
CHANGE OF NAME Recorded Nov 7, 2023
From: OLATEC THERAPEUTICS LLC
To: OLATEC THERAPEUTICS, INC.
Reel/Frame 065489/0809 →
CHANGE OF NAME Recorded Mar 18, 2016
From: OLATEC INDUSTRIES LLC
To: OLATEC THERAPEUTICS LLC
Reel/Frame 038177/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2011
From: ST. LAURENT, JOSEPH
To: OLATEC INDUSTRIES LLC
Reel/Frame 027394/0023 →
Continuity (2)
Provisional Application 61423485 · Dec 15, 2010
Related Publication 20120157524A1 · Jun 21, 2012